Supplemental Table 2. Real-world time on treatment among patients with R/M HNSCC who initiated second-line systemic therapy on or before December 31, 2018

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  |  | Second-line therapy | | |
|  |  | All patients  (N=454) | I-O monotherapy  (N=299) | Non-I-O therapy  (N=147) |
| Discontinued, N (%) |  | 412 (90.7%) | 261 (87.3%) | 143 (97.3%) |
| Patient follow-up, months A |  | 7.0 (6.2 - 7.7) | 6.4 (5.0 - 7.4) | 9.2 (7.2 - 11.0) |
| Time on treatment, months B |  | 2.1 (1.9 - 2.4) | 2.6 (2.1 - 2.9) | 1.8 (1.4 - 2.2) |
| On-treatment rate C |  |  |  |  |
| 6 months |  | 18.4% (14.9 - 22.1) | 24.8% (20.0 - 30.0) | 5.66% (2.65 - 10.3) |
| 12 months |  | 11.0% (8.26 - 14.2) | 16.1% (12.1 - 20.7) | 1.41% (0.28 - 4.58) |
| 18 months |  | 7.00% (4.74 - 9.83) | 10.5% (7.09 - 14.6) | - |

I-O, immuno-oncology

A Patient follow-up was defined as time from second-line initiation to date of death or data cutoff, whichever occurred first. Values are presented as median (95% CI) months.

B Time on second-line therapy. Values are presented as median (95% CI). Based on the Kaplan-Meier time-to-event model.

C Values are presented as percent (95% CI). Based on the Kaplan-Meier time-to-event model.